Today

Worksport completed two registered direct offerings, issuing common stock and warrants for total gross proceeds of approximately $722,870, leading to immediate and potential future dilution.

Pyxis Oncology is raising $50 million through a private placement of common stock and warrants, with potential for an additional $64 million from warrant exercise.

Bone Biologics Corp completed a private offering of pre-funded warrants and common stock warrants, raising $2.7 million in net proceeds but creating substantial potential future dilution.

S&W Seed Company announced its decision to voluntarily delist its common stock from Nasdaq and deregister with the SEC, citing financial burdens and likely future non-compliance.

LuxUrban Hotels Inc. received a delisting determination from Nasdaq due to its low stock bid price and failure to timely file its quarterly report, but plans to appeal by August 30, 2024.

Ribbon Acquisition Corp. shareholders will vote on amending the trust agreement to adjust monthly extension contributions, impacting the SPAC's deadline.

Advantage Solutions Inc. shareholders will vote on a reverse stock split to potentially regain compliance with listing standards.

AMC shareholders are voting on proposals to increase authorized shares and enact a 1-for-10 reverse stock split.

Outlook Therapeutics shareholders will vote on proposals to authorize share issuance for warrants, increase authorized shares, and enact a reverse stock split.

Kimmeridge is soliciting proxies for a contested election of three directors and several governance changes at SilverBow Resources' annual meeting.

VivoSim Labs, INC.'s S-1/A registration statement became effective; investors should review the original registration filing for securities, holders, and transaction terms.

VivoSim Labs is conducting a best efforts offering of units, with significant potential dilution from common warrants that include a cashless exercise provision.

VivoSim Labs is registering a mixed offering of common stock, pre-funded warrants, and common warrants, with a significant potential for future dilution from warrant exercises.

HCW Biologics filed an S-1/A to register up to 7.69 million Units, each with a share or pre-funded warrant and a common stock warrant, indicating substantial potential dilution.

Liminatus Pharma's mixed offering of common stock, pre-funded warrants, and accompanying warrants presents substantial potential dilution, with contingent exercise terms.

Ernexa Therapeutics is offering up to 13.6 million units and additional agent shares, creating substantial potential dilution, with an assumed offering price of $0.92 per unit.

This mixed offering includes a primary sale of common stock or pre-funded warrants, accompanied by Series X Warrants and Placement Agent Warrants, creating substantial potential dilution.

Picard Medical is offering 21.1 million shares or pre-funded warrants, plus 42.2 million underlying common warrants, which could result in substantial dilution.

BioVie is offering 1.99 million Units or Pre-funded Units, each with a warrant, at an assumed price of $7.55 per Unit, with final pricing pending.

RYVYL Inc. is offering up to $8 million in units, including pre-funded warrants with a nominal exercise price, leading to substantial potential dilution.